Abeona's ZEVASKYN approval and a $3.1 million price point are undervalued by the market. Find out why ABEO stock is a Buy.

Recessive dystrophic epidermolysis bullosa is a rare and serious condition. Zevaskyn is the first FDA-approved treatment for RDEB wounds with a single application. The FDA has approved Zevaskyn ...

On April 29, 2025, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) for the treatment of wounds in ...

FDA approval of Zevaskyn was based on findings from two clinical studies. In a single-center, open-label, phase 1/2a study involving 38 chronic wounds in seven patients, a single surgical ...

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (pronounced as ‘ZEE-vah ...

Abeona Therapeutics has received FDA approval for ZEVASKYN, the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a ...

The deal comes two weeks after the company picked up FDA approval for Zevaskyn to treat recessive dystrophic epidermolysis bullosa (RDEB), so it's likely some portion of the cash will be used to ...

Zevaskyn will have a weighted average cost of $3.1 million, according to a presentation from the company last month. Following the FDA approval in late April, the company said they will make Zevaskyn ...